Breakfast breakthrough: skipping doses may be possible for kidney cancer drug
NCT ID NCT05263245
First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 24 times
Summary
This study tested whether taking the kidney cancer drug cabozantinib with a light breakfast changes how much drug gets into the body. Twelve patients with advanced kidney cancer took the drug both with and without breakfast to compare drug levels. The goal is to find a dosing schedule that reduces side effects like nausea and diarrhea, and may allow skipping some doses to lower costs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Erasmus Medical Center
Rotterdam, South Holland, 3015 GD, Netherlands
-
Leids Universitair Medisch Centrum
Leiden, South Holland, 2333 ZA, Netherlands
Conditions
Explore the condition pages connected to this study.